We are live on ! Find out more
BIIB icon

Biogen

782 hedge funds and large institutions have $68.4B invested in Biogen in 2014 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 275 increasing their positions, 302 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 69

9% more funds holding in top 10

Funds holding in top 10: 3336 (+3)

4% more capital invested

Capital invested by funds: $66.1B → $68.4B (+$2.35B)

1% more funds holding

Funds holding: 776782 (+6)

9% less repeat investments, than reductions

Existing positions increased: 275 | Existing positions reduced: 302

25% less call options, than puts

Call options by funds: $814M | Put options by funds: $1.09B

Holders
782
Holders Change
+6
Holders Change %
+0.77%
% of All Funds
22.48%
Holding in Top 10
36
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+9.09%
% of All Funds
1.03%
New
81
Increased
275
Reduced
302
Closed
69
Calls
$814M
Puts
$1.09B
Net Calls
-$271M
Net Calls Change
+$35.6M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$573M +$65.7M +218,159 +14%
Wellington Management Group
27
Wellington Management Group
Massachusetts
$568M -$253M -840,786 -32%
BA
28
BlackRock Advisors
Delaware
$568M +$102M +339,384 +23%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$566M -$3.1M -10,305 -0.6%
Winslow Capital Management
30
Winslow Capital Management
Minnesota
$500M -$161M -536,290 -25%
Massachusetts Financial Services
31
Massachusetts Financial Services
Massachusetts
$497M +$76.1M +252,756 +19%
O
32
OppenheimerFunds
New York
$463M +$71.9M +238,880 +19%
American Century Companies
33
American Century Companies
Missouri
$442M +$133M +441,806 +46%
Goldman Sachs
34
Goldman Sachs
New York
$441M +$48.6M +161,425 +13%
MC
35
Montag & Caldwell
Georgia
$428M +$35.2M +116,960 +9%
CCI
36
Columbus Circle Investors
$425M +$4.3M +14,295 +1%
BIM
37
BlackRock Investment Management
Delaware
$367M +$126M +418,438 +56%
O
38
OrbiMed
New York
$342M +$7.07M +23,500 +2%
MAA
39
Managed Account Advisors
New Jersey
$338M -$18.1M -60,176 -5%
Allianz Asset Management
40
Allianz Asset Management
Germany
$334M +$15.9M +52,803 +5%
Legal & General Group
41
Legal & General Group
United Kingdom
$315M +$1.61M +5,362 +0.5%
Deutsche Bank
42
Deutsche Bank
Germany
$305M +$21.7M +72,226 +8%
Morgan Stanley
43
Morgan Stanley
New York
$295M +$41.7M +138,529 +17%
Prudential Financial
44
Prudential Financial
New Jersey
$288M +$3.23M +10,736 +1%
Grantham, Mayo, Van Otterloo & Co (GMO)
45
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$270M +$115M +380,800 +80%
Bank of America
46
Bank of America
North Carolina
$252M -$57.5M -191,097 -19%
AQR Capital Management
47
AQR Capital Management
Connecticut
$250M +$19.4M +64,600 +9%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$249M -$150K -498 -0.1%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$247M -$11.6M -38,699 -5%
BlackRock
50
BlackRock
New York
$239M +$14.9M +49,426 +7%

BIIB Hedge Fund Activity: Q2 2014 in Review

782 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q2 2014, worth a combined $68.4B — up 3.6% from $66.1B a quarter earlier.

Buyers outnumbered sellers: 81 funds opened new BIIB positions and 69 closed out — a net gain of 12 holders — while 275 added to existing stakes and 302 trimmed.

The largest buyer was Norges Bank, adding an estimated $493M. The largest seller was Wellington Management Group, cutting an estimated $253M.

  • 782 institutional investors held Biogen (BIIB) as of Q2 2014, up from 776 in Q1 2014.
  • Funds reported $68.4B of Biogen stock for Q2 2014, up 3.6% quarter-over-quarter.
  • 81 funds opened new Biogen positions in Q2 2014 and 69 closed out, a net change of +12 holders.
  • The largest Biogen buyer in Q2 2014 was Norges Bank, an estimated $493M added.
  • The largest Biogen seller in Q2 2014 was Wellington Management Group, an estimated $253M sold.

Based on aggregated 13F filings for Q2 2014.